Mind Medicine (MindMed), Inc. (MNMD)

Mind Medicine (MindMed), Inc. (MNMD) stock saw significant movement over the past six months, increasing by over 100% from July 1, 2025, to January 14, 2026, and reaching a 52-week high of $15.29 on January 8, 2026. Analyst ratings and price targets were updated by several brokerages, including Canaccord Genuity Group, Jones Trading, Royal Bank of Canada, and Lifesci Capital. The company reported its Q3 2025 financial results on November 6, 2025, missing analysts' consensus estimates for earnings per share. Insider Mark Sullivan sold 11,276 shares on December 26, 2025. The company rebranded to Definium Therapeutics, Inc. on January 12, 2026, with a ticker symbol change to DFTX. Topline data from three Phase 3 studies evaluating DT120 ODT for GAD and MDD are expected in 2026.

Specific demand seasonality information for Mind Medicine (MindMed), Inc.'s (now Definium Therapeutics, Inc.) products and services is not available, as its products are currently in development. However, the company's stock performance can exhibit seasonal patterns, though these patterns are based on past data and do not guarantee future performance.

Mind Medicine (MindMed), Inc. (MNMD), now known as Definium Therapeutics, Inc. (DFTX), was a clinical-stage biopharmaceutical company focused on developing novel treatments for brain health disorders, aiming to be a global leader in improving patient outcomes. Its pipeline included product candidates targeting neurotransmitter pathways crucial for brain health. The company rebranded to Definium Therapeutics, Inc. on January 12, 2026, with a new Nasdaq ticker symbol DFTX, reflecting a strategic focus on scientific rigor in advancing psychiatry. Major products under development include MM-120 (lysergide D-tartrate), in Phase 3 clinical trials for GAD and MDD with FDA Breakthrough Therapy Designation for GAD, and MM-402 (R(-)-MDMA), in Phase 1 clinical trials for ASD.

MindMed's headquarters are in New York, NY, with regional offices in Research Triangle Park, Durham, NC, and Carmel Valley, San Diego, CA. It also has subsidiaries in Basel, Switzerland (MindMed Discover) and Perth, Western Australia (MindMed Pty Ltd.).

Mind Medicine's reputation is tied to its clinical trial progress and focus on developing psychedelic and psychoplastogenic drugs for brain health disorders. The FDA's Breakthrough Therapy Designation for MM-120 (now DT120 ODT) for generalized anxiety disorder positively impacted its scientific and clinical reputation. The rebranding to Definium Therapeutics, Inc. aims to reinforce a reputation of disciplined execution and scientific leadership.

Mind Medicine (MindMed) Inc. (US:MNMD) has 307 institutional owners and shareholders holding a total of 44,367,714 shares, with institutional shareholders owning 40.33% of the stock, Mind Medicine insiders owning 45.42%, and retail investors owning 14.25%. Major institutional owners include BlackRock, Inc., Commodore Capital Lp, and Vanguard Group Inc. The largest individual shareholder is Stephen L. Hurst, who owns 40.72 million shares, representing 41.34% of the company.